Shingrix is linked to fewer heart events
A study of 72,000 older vaccinated adults found that Shingrix was associated with fewer cardiovascular events than the older Zostavax, but it was still observational.
60 秒版本
Researchers found an association between the newer shingles vaccine and lower cardiovascular risk compared with the older vaccine, but the evidence is not yet causal.
要点
- The comparison involved about 72,000 vaccinated adults aged 60 and older.
- Shingrix was associated with a 9 percent lower combined cardiovascular burden after seven years.
- The absolute difference was about one percentage point.
结论. The signal is worth testing in randomized trials; it should not be used to promise cardiovascular protection to an individual.
Researchers found an association between the newer shingles vaccine and lower cardiovascular risk compared with the older vaccine, but the evidence is not yet causal.
iyu explainerA natural comparison
The researchers used the 2017 transition from Zostavax to Shingrix as a natural experiment. They compared matched groups of adults aged 60 and older vaccinated shortly before or after the change.
iyu explainerWhat the study saw
Across roughly 72,000 people in electronic health records, the Shingrix group had a 9 percent lower combined burden of coronary disease, heart failure and stroke after seven years. The absolute difference was about one percentage point.
iyu explainerWhy it is not proof
The study remains observational. The network did not include people with public insurance, and unmeasured differences between groups can remain even after matching. The mechanism is also uncertain.
iyu explainerThe next test
Researchers are awaiting randomized evidence, including the Danish DAN ZOSTER study of about 162,000 people, with first results anticipated in 2027.
The immediate takeaway is a promising signal, not a new heart-disease prescription.